Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA

SHANGHAI and HONG KONG, Dec. 27, 2022. Antengene Corporation Limited ( " Antengene " ), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials